BPGbio Presents Key Advances in Its Oncology Pipeline Related to the NAi Interrogative Biology Platform at AACR 2024 Meeting

Insightful data comes from collaborations with Stanford University, University of Tennessee, Oak Ridge National Laboratory, and leading hospitals in Mexico across various stages of development.

On April 5, 2024, BPGbio, Inc., a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, announced the application of its NAi Interrogative Biology® Platform across several drug and diagnostic applications, following successful collaborations with Stanford University, University of Tennessee, Oak Ridge National Laboratory, and several leading hospitals across Mexico. The company presented four posters showcasing these research collaborations and provided updates on other internal research activities at the American Association for Cancer Research (AACR) Annual Meeting held April 5-10, 2024, in San Diego, California. 

Login Or Register To Read Full Story